Vicagrel

维卡格雷

Vicagrel

V655030-1ml

1ml

10mM in DMSO

-80℃储存

超低温冰袋运输

Vicagrel is a potent, safe and orally active antiplatelet agent, which works by irreversibly inhibiting P2Y12 receptor. Vicagrel can be used for the research of blood clots in coronary artery disease, peripheral vascular disease, and cerebrovascular disease. In Vitro Vicagrel (compound 9a) (20 μM, 30 min) activates production of the active metabolite from in vitro rat liver microsomal. MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Vicagrel (compound 9a) (oral, 3 mg/kg) has inhibitory effect on ADP-induced platelet aggregation in rats . Vicagrel (oral, 1.14 mg/mL, 0-24 h) has giood preliminary pharmacokinetic with high bioavailability and low clinically effective dose . Vicagrel (oral, 5 g/kg, single, for 14 days) has low dose-related toxicity in mouse . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (200−250 g) Dosage: 3 mg/kg Administration: oral Result: Inhibitied platelet aggregation by ADP-induced in rats. Animal Model: SD male rats Dosage: 1.14 mg/mL Administration: oral, 0-24 h Result: Could be readily converted into clopidogrel thiolactone and had high bioavailability. Animal Model: Mice Dosage: 5 g/kg Administration: oral, single, for 14 days Result: Had very low acute toxicity.

Vicagrel 是一种强效、安全、口服活性抗血小板药物，通过不可逆地抑制 P2Y12 受体发挥作用。Vicagrel 可用于研究冠状动脉疾病、外周血管疾病和脑血管疾病中的血栓。

1314081-53-2(DMSO)

C18H18ClNO4S

379.86 g/mol

CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3Cl)C(=O)OC